Das M, Musetti S, Huang L. RNA interference-based cancer drugs: the roadblocks, and the "delivery" of the promise. Nucleic Acid Ther. 2019 Apr;29(2):61-6. doi: 10.1089/nat.2018.0762
Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock S. Treatment interruption and regimen change in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. JHEOR. 2015 Apr;2(2):181-91.
Davis KL, Gutierrez B, Zyczynski T, Kaye JA. Real-world treatment patterns in men with castration-resistant prostate cancer receiving docetaxel. JHEOR. 2015 Jan 6;2(2):119-30. doi: 10.36469/9894
López MV, Rivero E, Serra C, Campo M, Raurich M, Bonfill X. Health survey in health care professionals in Barcelona. Arch Prev Riesgos Laborales. 1998;1(2):55-62.